Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its
The post Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal appeared first on Pharmaceutical Business review.
Original Article: Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal